Skip to main content

Table 1 Baseline characteristics of the sample

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Characteristics

Whole sample

Total (n = 1097)

Low MCP-1

(n = 823)

High MCP-1a

(n = 274)

Low Aβ42/40

(n = 137)

High Aβ42/40b

(n = 292)

Women, No. (%)d

700 (63.81%)

531 (64.52%)

169 (61.68%)

182 (73.09%)

110 (61.11%)

Age, yearsc,d

75.30 (4.37)

74.94 (4.21)

76.38 (4.66)

76.49 (4.77)

75.40 (4.44)

MAPT group allocation, No. (%)d

 Omega 3 + MDI group

274 (24.98%)

212 (25.76%)

62 (22.63%)

87 (29.79%)

27 (19.71%)

 Omega 3 group

267 (24.34%)

203 (24.67%)

64 (23.36%)

64 (21.92%)

37 (27.01%)

 MDI group

277 (25.25%)

198 (24.06%)

79 (28.83%)

77 (26.37%)

27 (19.71%)

 Control group

279 (25.43%°

210 (25.52%)

69 25.18%)

64 (21.92%)

46 (33.58%)

Education, No. (%)d

 No diploma

49 (4.54%)

37 (4.57%)

12 (4.43%)

4 (2.96%)

13 (4.51%)

 Primary school certificate

179 (16.57%)

133 (16.44%)

46 (16.97%)

38 (28.15%)

47 (16.32%)

 Secondary education

354 (32.78%)

256 (31.64%)

98 (36.16%)

52 (38.52%)

84 (29.17%)

 High school diploma

168 (15.56%)

135 (16.69%)

33 (12.18%)

10 (7.41%)

51 (17.71%)

 University level

330 (30.56%)

248 (30.66%)

82 (30.26%)

31 (22.96%)

93 (32.29%)

Body mass indexc,e

26.21 (4.05)

26.03 (3.95)

26.75 (4.32)

26.11 (3.51)

26.58 (4.23)

Composite cognitive scorec,f

0.023 (0.69)

0.05 (0.67)

−0.05 (0.75)

−0.22 (0.73)

−0.11 (0.75)

CDR Sum of boxes, range 0–18c

0.39 (0.59)

0.35 (0.55)

0.49 (0.69)

0.53 (0.66)

0.47 (0.67)

CDR status, No. (%)c

 No cognitive impairment, CDR score, 0

580 (52.97%)

456 (55.47%)

124 (45.42%)

151 (98.69%)

86 (98.85%)

 Mild cognitive impairment, CDR score, 0.5

509 (46.48%)

362 (44.04%)

147 (53.85%)

2 (1.31%)

1 (1.15%)

 Major cognitive impairment, CDR score, ≥ 1

6 (0.55%)

4 (0.49%)

2 (0.73%)

0 (0%)

0 (0%)

MMSE score, range 0–30

28.07 (1.81)

28.10 (1.74)

27.98 (2.01)

27.61 (1.88)

27.92 (1.92)

FCSRT free recall, range 0–48c,d

30.38 (7.52)

30.77 (7.17)

29.23 (8.39)

27.54 (8.42)

29.25 (7.86)

FCSRT total recall, range 0–48

45.72 (3.80)

45.83 (3.56)

45.40 (4.42)

44.45 (4.85)

45.38 (4.71)

FCSRT free delayed recall, range 0–16

11.48 (2.99)

11.53 (2.90)

11.33 (3.26)

10.47 (3.48)

10.95 (3.08)

FCSRT total delayed recall, range 0–16

15.52 (1.25)

15.53 (1.22)

15.46 (1.33)

15.19 (1.55)

15.37 (1.58)

APOE ε4 genotype, No. (%)d

 APOE ε4 carriers

226 (22.89%)

168 (20.4%)

58 (21.2%)

45 (33.83%)

58 (22.83%)

 Non-APOE ε4 carriers

761 (77.11%)

572 (79.6%)

189 (79.8%)

88 (66.17%)

196 (77.17%)

  1. Abbreviations: Amyloid-β, ADCS-ADL Alzheimer Disease Cooperative Study–Activities of Daily Living, APOE Apolipoprotein E, CDR Clinical Dementia Rating, MDI Multi-Domain Intervention, MMSE Mini-Mental State Examination
  2. aHigh-plasma MCP-1 defined as values in the 4th quartile
  3. bLow-plasma Aβ42/40 defined as values ≤ 0.107
  4. cP < .05 based on Student t test or Pearson χ2 test (between MCP-1 groups)
  5. dP < .05 based on Student t test or Pearson χ2 test (between Aβ42/40 groups)
  6. eBody mass index calculated as weight in kilograms divided by height in meters squared
  7. fBased on the z-score of 4 cognitive tests (free and total recall of the Free and Cued Selective Reminding test, 10 MMSE orientation items, Digit Symbol Substitution Test, and Category Naming Test)